Club Cell Protein, CC10, Attenuates Acute Respiratory Distress Syndrome Induced by Smoke Inhalation

Area of Science:

• Pulmonary Medicine
• Critical Care Medicine
• Translational Research

Background:

• Acute Respiratory Distress Syndrome (ARDS) is a severe lung condition often caused by smoke inhalation injury (SII).
• Current treatments for ARDS have limitations, necessitating the exploration of novel therapeutic agents.
• Recombinant human Club cell 10-kDa protein (rhCC10) has shown anti-inflammatory properties in preclinical models.

Purpose of the Study:

• To evaluate the dose-dependent effects of rhCC10 on lung function and inflammation in an ovine model of SII-induced ARDS.
• To determine the protective potential of rhCC10 against pulmonary tissue damage and dysfunction following SII.
• To assess rhCC10's ability to control the inflammatory response in ARDS.

Main Methods:

• A randomized, controlled, prospective study was conducted in 36 adult female sheep.
• ARDS was induced by smoke inhalation injury (SII), followed by treatment with varying doses of intravenous rhCC10 (1, 3, or 10 mg/kg/d) or vehicle.
• Lung function, airway inflammation, and systemic fluid leakage were monitored for 48 hours.

Main Results:

• The highest dose of rhCC10 (10 mg/kg/d) significantly attenuated the decline in PaO2/FiO2 ratio and oxygenation index.
• rhCC10 treatment reduced neutrophil infiltration in the airways, myeloperoxidase levels, and airway obstruction.
• High-dose rhCC10 significantly decreased systemic fluid and protein extravasation, mitigating pulmonary edema and normalizing fluid balance.

Conclusions:

• High-dose rhCC10 effectively attenuated ARDS progression and lung dysfunction in a large animal model.
• rhCC10 demonstrated significant reduction in systemic inflammation and fluid leakage, suggesting a protective role in ARDS.
• rhCC10 represents a potential novel therapeutic strategy for managing SII-induced ARDS.